Current Report Filing (8-k)
December 08 2017 - 5:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): December 7, 2017
CASI PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in
its Charter)
DELAWARE
(State or other jurisdiction of
incorporation or organization)
|
0-20713
(Commission File Number)
|
58-1959440
(IRS Employer Identification
No.)
|
9620 Medical Center Drive, Suite 300
Rockville, Maryland
(Address of principal
executive offices)
20850
(Zip Code)
(240) 864-2600
(Registrant’s
telephone number, including area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02.
|
Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On December 7, 2017, the Compensation
Committee of the Board of Directors of CASI Pharmaceuticals, Inc. (the “Company”) approved the payment of year-end
cash bonuses of (1) $370,000 to Dr. Ken K. Ren, the Company’s Chief Executive Officer and (2) $660,000 to Dr. Wei-Wu
He, the Chairman of the Board of Directors.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CASI PHARMACEUTICALS, INC.
|
|
|
|
/s/ Sara B. Capitelli
|
|
|
|
Sara B. Capitelli
|
|
Vice President, Finance and Principal Accounting Officer
|
Date: December 8, 2017
CASI Pharmaceuticals (NASDAQ:CASI)
Historical Stock Chart
From Aug 2024 to Sep 2024
CASI Pharmaceuticals (NASDAQ:CASI)
Historical Stock Chart
From Sep 2023 to Sep 2024